Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative…
Year: 2022
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a…
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose…
Enzo Biochem Adjourns Annual Meeting of Shareholders Until April 8, 2022
NEW YORK, NY, April 01, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo”…
Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results
CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified…
Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company…
Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021
LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused…
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy
SAN FRANCISCO, April 01, 2022 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing…
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform MALVERN, Pa.,…
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in…
ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022
RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) — ADMA Biologics, Inc….
Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes
Experimental trial research presented at the American College of Cardiology’s 71st Annual Scientific Session showed…
Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) — Petros Pharmaceuticals, Inc. (“Petros” or “the Company”)…
Philogen Reports Full Year 2021 Results and Provides Corporate Update
Philogen Reports Full Year 2021 Results and Provides Corporate Update Patient enrolment in Nidlegy™’s European…
Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company…
Plurilock Names Garr Stephenson Jr. as Chief Revenue Officer
Vancouver, British Columbia–(Newsfile Corp. – April 1, 2022) – Plurilock Security Inc. (TSXV: PLUR) (OTCQB:…
Cylum Launches Highest APY Staking Reward in the Crypto Space
London, UK, Apr 1, 2022 – (ACN Newswire) – Cylum Finance, a DeFi 3.0 platform,…
UPGRADE Announces Date for Its Whitelist, Presale, and Public Sale Events
Bangkok, Thailand, Apr 1, 2022 – (ACN Newswire) – UPGRADE, a platform that enables NFT…
Resintech Bhd Proposes Bonus Share and Warrant Issues
KUALA LUMPUR, Apr 1, 2022 – (ACN Newswire) – Resintech Berhad (7232; RESINTC), a fully…
Smart Eye Partners with Psychology Software Tools to Deliver New Eye Tracker Solution to Enhance Speed and Accuracy of Research
PITTSBURGH & GOTHENBURG, Sweden–(BUSINESS WIRE)–Today, Smart Eye, the global leader in Human Insight AI, technology…